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Abstract
Background and Objectives: The aim of this study was to estimate the proportion of spontaneous viral clearance (SVC)
after symptomatic acute hepatitis C and to evaluate the efficacy of 12 weeks of pegylated interferon alfa-2a in patients who
did not clear the virus spontaneously.
Methods: Patients with symptomatic acute hepatitis C were recruited from two ‘‘fever hospitals’’ in Cairo, Egypt. Patients
still viremic three months after the onset of symptoms were considered for treatment with 12 weeks of pegylated interferon
alfa-2a (180 mg/week).
Results: Between May 2002 and February 2006, 2243 adult patients with acute hepatitis were enrolled in the study. The SVC
rate among 117 patients with acute hepatitis C was 33.8% (95%CI [25.9%–43.2%]) at three months and 41.5% (95%CI
[33.0%–51.2%]) at six months. The sustained virological response (SVR) rate among the 17 patients who started treatment
4–6 months after onset of symptoms was 15/17=88.2% (95%CI [63.6%–98.5%]).
Conclusion: Spontaneous viral clearance was high (41.5% six months after the onset of symptoms) in this population with
symptomatic acute hepatitis C. Allowing time for spontaneous clearance should be considered before treatment is initiated
for symptomatic acute hepatitis C.
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Introduction
Management ofacute hepatitisC is a complex issue.While studies
have shown that treatment during the acute phase can achieve high
(72%–98%) success rates [1–9], the optimal regimen and timing of
treatment are still a matter of debate [10–13]. One crucial issue that
remains to be resolved is whether physicians should treat all patients
diagnosed with acute hepatitis C, or should wait and treat only those
who failed to clear the virus in the first few months after infection.
Among recently published studies (2006–7) [5–9], the trend hasbeen
to treat early (i.e., within three months of infection or one month of
onset of symptoms), and with simplified regimens (12 or 24 weeks of
monotherapy with pegylated interferon). In these studies, intrave-
nous drug use and occupational exposure were the main risk factors
for infection, and the majority of patients were a- or pauci-
symptomatic, except for the German HEP-NET study, where
recruitment wasmorediverseand patients withjaundice represented
62% of all cases [6].
In Egypt, the epidemiological situation differs from that of
Western countries. HCV prevalence is very high (estimated among
adults at 10 and 20% in urban and rural areas respectively) [14].
The origin of the epidemic has been attributed to mass campaigns
of parenteral anti-schistosomiasis treatment in rural areas in the
1960s–70s. Since the virus has continued to spread, mainly
through intravenous injections and other medical procedures [15],
acute hepatitis C is commonly diagnosed among patients
presenting with jaundice [16]
Among these patients, waiting for spontaneous clearance and
treating only those still viremic three months after the onset of
symptoms makes sense for two reasons: the higher rate of
spontaneous clearance expected from patients with symptomatic
compared to asymptomatic forms of acute hepatitis C (estimated at
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e408531% versus 18%, respectively, 17); and the cost savings incurred
by not treating all patients, an important consideration in
countries with limited resources, including Egypt. In this paper,
we present the results of the follow-up of 117 patients diagnosed
with symptomatic acute hepatitis C in Cairo. Patients who failed to
clear the virus three months after the onset of symptoms were
considered for treatment with 12 weeks of pegylated interferon
alfa-2a.
Methods
Study population and questionnaire
The recruitment of patients with symptomatic acute hepatitis C
has already been described in our previous report of a pilot study
performed in 2002 in Cairo [16]. Adjustments to the protocol were
made at the end of the pilot study, and the main components of
the study are presented here. Patients were recruited from two
‘‘fever hospitals’’ (Abbassia and Imbaba Fever Hospitals), which
are public hospitals specialized in infectious diseases offering care
at moderate cost to the disadvantaged populations of Cairo.
Inclusion criteria were age above 18 years, symptoms (fever or
jaundice) lasting less than 21 days, and elevated serum alanine
aminotransferase (ALT) $3 times the upper limit of normal
(ULN=40 IU/L).
All patients were interviewed by trained medical doctors, using
a questionnaire on socio-demographic characteristics and risk
factors for HCV infection in the past six months. Risk factors were
categorized as high risk and low risk exposures based on the
magnitude of the associations with HCV transmission documented
in previous studies [15,16]. High risk exposures included surgery,
blood transfusion, hemodialysis, biopsy, endoscopy, Caesarean
section, episiotomy, uterine curettage, injection, infusion, catheter,
sclerotherapy of varicose veins, and dental care. Low risk
exposures included acupuncture, shaving at barber, tattooing,
pedicure, manicure, and circumcision. Also assessed was exposure
to other potential causes of hepatitis, including drugs, pesticides,
and other chemicals known for their hepatotoxicity.
Laboratory methods
A 10 ml venous blood sample was collected for liver functions
[ALT, aspartate aminotransferase (AST), total and indirect
bilirubin, alkaline phosphatase], and exclusion of acute hepatitis
A and B by serological analysis [IgM anti-hepatitis A virus (HAV)
(HAVABH, M EIA, Abbott Laboratories, Diagnostics Division,
Abbott Park, IL); IgM anti-hepatitis B virus (HBV) core
(CORZYMEH, M rDNA, Abbott Laboratories, Diagnostics
Division); hepatitis B surface antigen (AUSZYME MONOCLO-
NALH, third generation EIA, Abbott laboratories, Diagnostics
Division, Abbott Park, IL)]. In patients with non-A non-B
hepatitis, anti-HCV antibodies were assessed serologically (IN-
NOTESTH HCV Ab IV, Innogenetics, Ghent, Belgium), and
HCV RNA Extraction was performed using QIAmp Viral RNA
Kit (QIAGEN, Santa Clarita, U.S.A.) according to manufacturer’s
recommendations. The Reverse Transcription and Polymerase
Chain Reaction (RT-PCR) was done according to Abdel-Hamid
et al, 1997 [18] with some modifications to increase the sensitivity
of the assay (50 IU/mL). The RT and first round of PCR
amplification were performed in a single step as follows: the RT-
PCR master mix consisted of 1X Taq buffer with 1.5 mM MgCl2
(Roche Molecular Biochemicals), 0.2 mM dNTP (Promega), 20
pmol of each primer (P1 and P2), 20 U of Human Placental
Ribonuclease Inhibitor (RNasin, Promega), 10 U of AMV reverse
transcriptase (Promega), and 2.5 U of Taq DNA polymerase
(Roche Molecular Biochemicals). The master mix was added to
55 ml of RNA from each sample, and the tubes were subjected to
the following thermal cycles: 42uC for 30 minutes (one cycle) for
RT, 35 cycles at 94uC for denaturation for 1 minute, 50uC
annealing for 1 minute, and 72uC extension for 1 minute and a
final extension step at 72uC for 10 minutes (one cycle). Nested
PCR was conducted with 10 ml of the first PCR reaction added to
90 ml of the master mix, consisting of the same reagents used in the
first PCR expect for using P-3 and P-4 and without adding RT or
RNasin. Thermo cycling for 35 cycles was performed as in the first
PCR but without the initial RT step. The outer (P-1, P-2) and
inner primers (P-3, P-4) for the nested PCR reaction were derived
from the highly conserved 59 untranslated region (59UTR) of the
HCV genome. PCR results were visualized by electrophoresis
using ethidium bromide in a 3% agarose gel.
In patients with positive HCV antibodies and RNA, exacerba-
tion of chronic hepatitis C by other infectious agents was ruled out
using reverse transcriptase PCR for HEV-RNA (in house assay
using ORF1 and ORF2 primers) and serological testing [anti
Epstein-Barr virus (EBV) IgM (ETI-EBV-M reverse P001605, Dia
Sorin, Vercelle, Italy), anti-cytomegalovirus (CMV) IgM (AX-
SYMH system-CMV-IgM, Abbott Laboratories, Wiesbaden,
Delknheim, Germany), and anti-Toxoplasma IgM (AXSYMH
system-Toxo-IgM, Abbott Laboratories, Wiesbaden, Delknheim,
Germany)]. All tests were performed at the Viral Reference
Hepatology Laboratory (VHRL).
Definitions of acute hepatitis C
The diagnosis of acute hepatitis C was based on epidemiological
findings, clinical examination, and laboratory test results. Accord-
ingly, patients were categorized as 1) Definite acute hepatitis C if
negative anti-HCV antibody and positive HCV RNA; 2) Probable
acute hepatitis C if positive anti-HCV antibody and HCV RNA
associated with ALT$10 times the ULN, history of high risk
exposure 1 to 3 months prior to diagnosis, negative serology/PCR
(see above) for other infectious agents (HAV, HBV, HEV, EBV,
CMV, toxoplasmosis), no history of drugs or pesticides exposure,
and no other cause of hepatitis (e.g., autoimmune hepatitis,
ischemic liver injury, Wilson disease).
Follow-up
All patients with acute hepatitis C were offered follow-up at the
National Hepatology and Tropical Medicine Research Institute
(NHTMRI) in Cairo. Visits were scheduled for clinical and
biochemical assessment at 2, 3, 6, 12, 18 and 24 months,
calculated from onset of symptoms. Antiviral treatment was not
offered immediately in order to allow for spontaneous clearance of
the virus; however, non-specific symptomatic treatment, such as
antiemetics for nausea and vomiting, antipyretics for fever and
analgesics for headache, were offered to all patients. Patients who
were still HCV RNA positive three months after the onset of
symptoms were screened for treatment eligibility. Exclusion
criteria for treatment were age ,18 years or .65 years; poorly
controlled diabetes; thyroid disease (TSH outside the normal
range); autoimmune diseases; alcoholism; liver cirrhosis; hepato-
cellular carcinoma; psychiatric disease such as history of severe
depression, psychosis, suicidal ideas; epilepsy; non-stabilized
medical or surgical condition; hemoglobin,11 g/dl, leucocytes
,3000/mL, polynuclear neutrophils ,1500/mL, platelets ,100
000/mL, and blood creatinin .150 mmol/L. For females:
pregnancy or breastfeeding were contra-indications (an effective
contraception was requested during the treatment period).
Treatment with free pegylated interferon [PEG-IFNa-2a
(PEGASYSH, Roche)] (180 mg/week) for 12 weeks was started
4–6 months after onset of symptoms in those still positive at that
Acute HCV Clearance &Treatment
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provided at the NHTMRI clinic under medical supervision. In
patients still HCV RNA positive after 12 weeks of treatment,
treatment was extended for another 12 weeks. Patients were seen
weekly during the treatment period, and every six weeks
afterwards until week 36 (end of follow-up for those treated for
12 weeks), or week 48 (end of follow-up for those treated for 24
weeks). The dosage of PEG-IFN a-2a was reduced for two weeks
to 90 mg/week if neutrophil or platelet counts fell below 750/mL
and 50,000/mL, respectively. After the 2 weeks, dose was raised
back to 180 mg/week if neutrophil and platelet counts went above
750/mL and 50,000/mL, respectively. Treatment was discontinued
if neutrophil or platelet counts fell below 500/mL and 25000/mL,
respectively, or when serum hemoglobin concentrations decreased
below 8.5 g/dL. Doctors’ judgment was the basis for dose
reduction and discontinuation of PEG-IFN a-2a if other
commonly reported adverse events (such as flu-like symptoms
and emotional side effects) were reported. The primary endpoint
was sustained virological response (SVR), defined as negative
serum HCV RNA 24 weeks after the end of treatment. Secondary
endpoints were the absence of detectable levels of serum HCV
RNA at the end of treatment and the normalization of ALT levels.
Viral load was determined using the Cobas Amplicor HCV
Monitor test, v 2.0 (Roche Diagnostic Systems).
Ethics
All patients with acute hepatitis consulting or hospitalized in the
two participating hospitals were included in the study after
providing a written informed consent. A separate informed
consent was required for the patients who were treated with
pegylated interferon. The entire study protocol has obtained
clearance from the Ministry of Health and Population in Egypt,
and the Institutional Review Board for Human Subject Research
at NHTMRI. The 12-week pegylated interferon trial protocol for
patients with acute hepatitis C has been registered under the
following number: NCT00158522 (ANRS1213).
Statistical Analysis
Spontaneous viral clearance (SVC) was defined as no HCV
RNA in serum, in the absence of treatment, for two consecutive
HCV PCR tests during follow-up. Patients treated with pegylated
interferon were censored at the time of treatment initiation. Date
of clearance was chosen as the midpoint between the last positive
PCR and the first negative PCR defining clearance. The SVC rate
was estimated using Kaplan-Meier estimates, with time 0
equivalent to onset of symptoms. A Cox proportional hazards
model was used to identify factors associated with SVC. Factors
with p values less than 0.25 in univariate analysis were tested in the
multivariate model, and p values less than 0.05 were considered
significant. Statistical analyses were performed using Stata 8
statistical software (Stata Corporation, College Station, Texas,
USA).
Results
Diagnosis of acute hepatitis C (Figure 1)
Between May 2002 and February 2006, 2243 consecutive adult
patients with acute hepatitis were recruited from Abbassia and
Imbaba Fever Hospitals. Of these, 647 (28.8%) were diagnosed
with acute hepatitis A, 609 (27.2%) were diagnosed with acute
hepatitis B, and 401 (17.9%) tested positive for HCV RNA by
PCR. Of the patients positive for HCV RNA, those with negative
HCV antibodies (n=79; 3.5% of the initial 2243 patients) were
considered as definite acute hepatitis C. Of the 322 with positive
HCV antibodies, 114 had ALT levels lower than 10 times ULN,
and were therefore no longer considered potential acute hepatitis
C cases. Full assessment to determine final status (serologies/PCR;
see Patients and methods) was performed for the remaining 208
patients, and 81 were diagnosed with probable acute hepatitis C.
Therefore, the overall proportion [95% CI] of acute hepatitis C
among all acute hepatitis adult patients was 160 (i.e., 79+81)/
2243=7.1% [6.1%–8.3%].
Follow-up
Follow-up data were available for 117 (73.1%) of the 160
patients with acute hepatitis C. Table 1 displays the socio-
demographic, clinical, and biological characteristics of the 160
acute hepatitis C patients. There was no difference in these
characteristics among acute hepatitis C cases followed-up and
those who were not, except for ALT level. Patients with probable
acute hepatitis C were all in the group with follow-up since
ascertainment of cases required follow-up to perform additional
serological and PCR investigations (see Patients and Methods). As
a result, patients with follow-up had higher median ALT level
when compared to those without follow-up since the definition of
probable acute hepatitis C included ALT .10 times the ULN.
The following is a description of the patients with follow up. The
mean age of patients was 34.6 years and 59% were males. Due to
the location of the fever hospitals in Cairo, the majority of patients
belonged to an urban population (78.1%). Forty percent were
illiterate, reflecting the low socio-economic status of patients
attending the fever hospitals. Nearly all patients presented with
jaundice (96.6%) and one third presented with fever (35.0%).
Median ALT level was above 15 times the upper limit of normal
(ULN). Potential sources of HCV infection were medical (n=77;
65.8%), dental (n=5; 4.3%), intravenous drug use (n=9; 7.7%),
low risk exposure (n=19; 16.2%), and unknown (n=7; 6.0%). Of
the potential medical sources of infection, surgery was the most
commonly reported (40/77=51.9%), and provided a precise
putative date of infection. The mean time from infection to onset
of symptoms was 1.6 months among these patients.
In total, 51 patients spontaneously cleared the virus, with the
following Kaplan-Meier estimates (95% CI) at specific points
during the follow-up period: 33.8% (25.9%–43.2%) at 3 months,
41.5% (33.0%–51.2%) at 6 months, 44.0% (35.2%–53.9%) at 12
months, 45.5% (36.5%–55.6%) at 18 months, and 47.3% (38.0%–
57.6%) at 24 months (Figure 2). For those who cleared the virus
spontaneously, median (IQR) time from onset of symptoms to
HCV RNA clearance was 66 (40–88) days, and 80.4% had cleared
the virus by day 96. Only 4 patients cleared the virus more than six
months after the onset of symptoms (at days 190, 321, 492, and
715). None of the studied risk factors (including age, gender,
clinical and laboratory findings, and source of infection) were
associated with SVC in univariate analysis (Table 2). In some
patients, atypical patterns of viremia were observed. Eighteen of
the patients with viral persistence had one negative result during
their period of follow up (8/18 before 3 months, 17/18 before 6
months). Finally, there were six patients who were considered as
relapsers, i.e., they had two consecutive negative PCR test results,
before becoming positive again. None of them were intravenous
drug users.
Treatment with 12-week pegylated interferon alfa-2a
From the 77 patients still HCV RNA positive three months after
the onset of symptoms, 17 were treated with pegylated interferon.
Sixty patients were not treated for the following reasons: 16 had
negative HCV RNA by PCR during the screening period (7 who
definitely cleared the virus and 9 who turned positive again during
Acute HCV Clearance &Treatment
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not show up at the pre-treatment screening visit but re-appeared at
subsequent follow-up visits more than six months after the onset of
symptoms, 6 were definitely lost to follow-up, and 4 refused
treatment. Seventeen patients started treatment with pegylated
interferon. Their baseline characteristics are summarized in
Table 3. All patients received all weekly injections they were
entitled to. No adverse event requiring hospitalization or dose
reduction was observed except for one patient whose dose was
reduced after 5 weeks of treatment as a result of neutropenia
(neutrophils=500/mL). Dose was reduced for two weeks and
returned back to 180 mg/week in the eighth week (neutro-
phils=1000/mL). This patient eventually achieved SVR. By the
end of the 12-week treatment, 15/17 (88.2%) had cleared the
virus. Treatment was continued for another 12 weeks for the 2
patients who tested HCV RNA positive at 12 weeks; one of them
remained HCV RNA positive for the rest of the follow-up while
the other cleared the virus between week 12 and week 24.
However, one patient who had cleared the virus by week 12
became HCV RNA positive again by week 24. The overall SVR
rate was 15/17=88.2% (95%CI=63.5%–98.5%). By week 12,
ALT were below the ULN (40 IU/L) in 12/17 (70.6%) patients (of
note, the highest value was 52 IU/L, still quite close to the ULN).
By 24 weeks after the end of treatment, ALT were normal in all
except the two viremic patients (65 and 305 IU/L, respectively).
Because of low study numbers, no attempt was made to look for
associations between baseline characteristics and SVR.
Discussion
Between May 2002 and February 2006, approximately 7% of
adult patients presenting with acute hepatitis in two hospitals of
CairohadacutehepatitisC.Inabsolutenumbers,around3casesper
monthwerediagnosedinthesetwohospitalsduringthestudyperiod.
This figure contrasts with the rarity of acute hepatitis C diagnoses in
Western countries. Most patients had recent exposure to invasive
medical procedures, half of which were surgical cases, suggesting the
need for strictpreventive measures to control this source of infection.
Figure 1. Diagnosis and follow-up of acute hepatitis C among 2243 patients with acute hepatitis, 2002–6, Cairo.
doi:10.1371/journal.pone.0004085.g001
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2002–6 (n=160).
Characteristics Completed Study (n=117) Lost to Follow up (n=43) P-value
Age (in years) #35 years 69 (59.0) 29 (67.4) 0.33
.35 years 48 (41.0) 14 (32.6)
Gender Female 48 (41.0) 19 (44.2) 0.75
Male 69 (59.0) 24 (55.8)
Residency Urban 89 (78.1) 35 (81.4) 0.65
Rural 25 (21.9 ) 8 (18.6)
Missing 3 0
Marital Status Ever married 86 (73.5) 26 (60.5) 0.14
Never married 31 (26.5) 17 (39.5)
Education Illiterate 46 (40.4) 17 (39.5) 0.14
Read and write 39 (34.2 ) 9 (21.0)
Formal education 29 (25.4) 17 (39.5)
Missing 3 0
Occupation Skilled labour 13 (11.3) 6 (14.0) 0.21
Unskilled labour 61 (53.0 ) 16 (37.2)
Not working 41 (35.7) 21 (48.8)
Missing 2 0
Fever Yes 41 (35.0) 16 (37.2) 0.91
No 76 (65.0) 27 (62.8)
Jaundice Yes 113 (96.6) 42 (97.7) 0.81
No 4 (3.4) 1 (2.30)
Laboratory Data Median (IQR) ALT (IU/L) 684 (515–904) 510 (299–650) 0.001
1
Median (IQR) total bilirubin (mg/dl) 7.2 (3.8–10.9)
2 9.1 (4.7–11.8) 0.29
1Patients with probable acute hepatitis C were all in the group with follow-up since ascertainment of cases required follow-up to perform additional serological and PCR
investigations (see Patients and Methods). As a result, patients with follow-up had higher median ALT level when compared to those without follow-up since the
definition of probable acute hepatitis C included ALT.10 times the ULN.
2Two missing values for bilirubin
doi:10.1371/journal.pone.0004085.t001
Figure 2. Kaplan-Meier estimate of the SVC rate among 117 patients with acute hepatitis C, 2002–6, Cairo.
doi:10.1371/journal.pone.0004085.g002
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hepatitis C, 41% had spontaneously cleared the virus six months
after onset of symptoms. This figure, found in a patient group
infected primarily with HCV genotype 4, is similar to the 41%
estimate obtained from a cohort of patients with symptomatic
community-acquired acute hepatitis C in Italy whose infecting
genotypes were: 1 (42%), 2 (20%), 3 (16%), 4 (2%), and unknown
(20%) [19]. Clearance after six months was a rare event in the
Egyptian cohort, occurring in just four patients, bringing the
overall spontaneous clearance rate estimate to 47.3% after two
years. Unfortunately, as is the case for the study performed in
Italy, no factors associated with SVC, which could serve as early
predictors during screening for treatment, could be identified.
One of the crucial issues in acute hepatitis C management is
when to treat. While randomized trials comparing different timing
of treatment initiation may be the most rigorous approach to the
issue, more than 200 patients in each arm would be required to
have 80% power to show a 10% difference (e.g., 80% versus 90%
SVR rates) between two strategies. Such sample sizes will be
difficult to achieve for a rare disease like acute hepatitis C.
Descriptive studies like this one may therefore be useful in making
educated guesses for patient management until the results of
randomized trials are available. In this study of symptomatic acute
hepatitis C, 80% of all SVC took place within three months after
onset of symptoms (or five months after infection taking into
account the two months average duration between infection and
symptoms). Thus, waiting for three months after onset of
symptoms to treat may be necessary in symptomatic acute
hepatitis C to allow SVC to take place. The question arises of
whether waiting so long after infection to provide treatment might
compromise the response of the patients who will ultimately need
it. A study in which treatment with interferon was initiated one
year after the onset of symptoms achieved a disappointing 40%
SVR rate [3]. However, waiting one year may have been
excessive, as suggested by the better results obtained in two other
studies with treatment starting at least three months after the onset
of symptoms. One, in which interferon-alfa was used alone or in
combination with ribavirin for a mean duration of 38 weeks,
achieved a 78% SVR rate among 18 patients who initiated
treatment in median 7.4 (IQR: 5.5–11.6) months after the onset of
symptoms [2]; another, in which 24 weeks of pegylated interferon
alfa-2b were used, achieved a 94% SVR rate in 16 patients who
initiated treatment after 12 weeks from onset of disease [4]. The
present study, the first one offering delayed treatment with only 12
weeks of pegylated interferon, compares well with these two
Table 2. Factors associated with spontaneous viral clearance in acute hepatitis C patients (n=117).
Characteristics SVC (n=51) Person-months Crude HR (95%CI) P-value
Age (in years) #35 31 652 1.00 0.47
.35 20 542 0.81 (0.46–1.43)
Gender Female 21 527 1.00 0.80
Male 30 667 1.07 (0.61–1.88)
Fever No 33 767 1 0.96
Yes 18 427 0.99 (0.55–1.75 )
Jaundice No 1 28 1 0.96
Yes 50 1166 1.05 (0.14–7.63)
Baseline ALT level #median
1 23 616 1 0.26
.median
1 28 578 1.37 (0.79–2.39)
Baseline bilirubin level #median
1 25 546 1 0.81
.median
1 25 647 0.93 (0.54–1.63)
Source of infection
2 Medical 31 804 1.00 0.69
Dental 3 75 1.51 (0.46–4.96)
IVDU 4 90 1.22 (0.43–3.46)
Low risk 11 168 1.61 (0.81–3.22)
Unknown 2 57 0.79 (0.19–3.31)
1Median ALT was 684 IU/L; median bilirubin was 7.2 mg/dl (two missing values for bilirubin).
2Medical procedures included surgery, blood transfusion, hemodialysis, biopsy, endoscopy, Caesarean section, episiotomy, uterine curettage, injection, infusion,
catheter, sclerotherapy of varicose veins. Low risk exposures included acupuncture, shaving at barber, tattooing, pedicure, manicure, and circumcision.
doi:10.1371/journal.pone.0004085.t002
Table 3. Characteristics of the 17 patients who underwent
treatment with pegylated interferon
Characteristics
Age (in years), median (IQR) 31 (27–38)
Males, n (%) 12 (70.6)
Weight (in kilos) , median (IQR) 85 (68–93)
Duration between onset of symptoms and
treatment (in months), median (IQR)
5.2 (4.3–6.2)
HCV genotype, n
4a 11
11
untypable 1
missing 4
ALT at treatment initiation (in IU/L), median (IQR) 85 (36–155)
Viral load at treatment initiation (in IU/mL), median
(IQR)
74400 (7900, 444000)
doi:10.1371/journal.pone.0004085.t003
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5.2 months after the onset of symptoms; treatment duration was
extended to 24 weeks in two patients). There is currently no
evidence, in the absence of HIV co-infection, that adding ribavirin
to pegylated interferon would improve these already high SVR
rates. In addition, it would expose patients to an increased risk of
anemia and their offspring to congenital abnormalities. In Egypt,
where the cost of drugs is a major issue, delaying treatment to
allow SVC and using only 12 weeks of pegylated interferon could
preserve much-needed resources. There are, however, two caveats
related to this strategy: patients may be lost to follow-up if not
immediately treated, and the fact that some patients have an
atypical pattern of viremia, with transient non detection of viremia
in the first six months after onset of symptoms. In this study, 18 of
the 66 patients who did not clear the virus spontaneously had
transient undetectable viremia during the first six months after
onset of symptoms. It is therefore crucial to repeat the HCV PCR
during the first six months of follow-up to confirm viral clearance
in patients who turn negative at one examination.
In conclusion, this study has documented the high spontaneous
clearance rate of symptomatic acute hepatitis C, and shown that
80% of SVC had taken place three months after onset of
symptoms. In patients who had not spontaneously cleared the
virus by that time, SVR could be obtained in 88.2% with a short
12-week monotherapy with pegylated interferon alfa-2a.
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